|
Re: Looks like 0 participation in warrant incentive imo - answer to my email...
|
4
|
Resverlogix Corp.
|
Jan 16, 2020 03:20PM
|
|
Re: Lu stepping down
|
6
|
Resverlogix Corp.
|
Feb 22, 2024 07:11PM
|
|
Re: Lu stepping down
|
5
|
Resverlogix Corp.
|
Feb 21, 2024 07:19PM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 04, 2018 10:46AM
|
|
Re: MACE Events - Statistically Confusing
|
2
|
Resverlogix Corp.
|
Mar 01, 2019 02:12PM
|
|
Re: March 18 PR lists two major clinical reflection points
|
7
|
Resverlogix Corp.
|
May 15, 2018 04:11PM
|
|
Re: Market Woes
|
8
|
Resverlogix Corp.
|
May 02, 2022 09:31PM
|
|
Re: Market:FDA Not Enough ??
|
5
|
Resverlogix Corp.
|
Jul 25, 2017 10:48AM
|
|
Re: Meanwhile...back at the outhouse :-)
|
4
|
Resverlogix Corp.
|
Sep 16, 2015 11:00AM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
5
|
Zenith Epigenetics
|
Jan 29, 2023 08:24AM
|
|
Re: MERCK….
|
5
|
Resverlogix Corp.
|
Oct 01, 2021 01:59PM
|
|
Re: MERCK….
|
3
|
Resverlogix Corp.
|
Oct 03, 2021 08:52PM
|
|
Re: MERCK….
|
4
|
Resverlogix Corp.
|
Oct 04, 2021 11:17AM
|
|
Re: MERK
|
9
|
Resverlogix Corp.
|
Sep 30, 2021 10:42AM
|
|
Re: Middle Eastern $
|
6
|
Resverlogix Corp.
|
Sep 03, 2023 04:18PM
|
|
Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
5
|
Zenith Epigenetics
|
Sep 02, 2018 12:14PM
|
|
Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
|
2
|
Zenith Epigenetics
|
Sep 02, 2018 12:14PM
|
|
Re: Momentum Players and Agoracom.com’s Rules
|
7
|
Resverlogix Corp.
|
Dec 21, 2021 11:52AM
|
|
Re: Month 10
|
6
|
Zenith Epigenetics
|
Apr 15, 2017 03:16PM
|
|
Re: More news on the way? They say things happen in 3s.....
|
3
|
Resverlogix Corp.
|
May 24, 2017 10:29AM
|
